title: The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
abstract: BACKGROUND
  The objective of this study was to evaluate the clinical outcome of a population-based cohort of immunocompetent patients with primary central nervous system lymphoma (PCNSL) treated with 3 different strategies over 13 years.
  
  
  METHODS
  One hundred twenty-two consecutive patients (median age, 66 years) with PCNSL were identified. Three treatment strategies were employed: 1) whole-brain irradiation with (from January, 1990, to June, 1991) or without (from April, 1995, to December, 1999) cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-type chemotherapy (n=50 patients); 2) combined-modality therapy, including 1 g/m2 methotrexate plus whole-brain irradiation (from July, 1991, to March, 1995; n=34 patients); and 3) 8 g/m2 methotrexate alone (from January, 2000, to March, 2003) with whole-brain irradiation reserved for those with progressive disease (n=38 patients). Treatment failure was defined as progressive disease, disease recurrence, death from toxicity or lymphoma, or toxicity that necessitated a change in primary treatment.
  
  
  RESULTS
  The median failure-free survival was 7 months, and the median overall survival (OS) was 17 months. The median OS was similar in all 3 eras. In this population-based analysis, one-third of patients did not receive the treatment strategy of the era. Therefore, the data also were analyzed by treatment received. On multivariate analysis (including era of treatment), 3 factors-age > 60 years, lactate dehydrogenase > normal, and omission of methotrexate-were associated significantly with poorer OS (hazard ratio: 2.3, 2.2, and 2.3, respectively).
  
  
  CONCLUSIONS
  Outcomes for a general population with PCNSL remained constant despite different treatment strategies over three eras. For the two-thirds of patients who could receive potentially curative treatment, age, lactate dehydrogenase level, and receipt of > or = 1 g/m2 methotrexate appeared to be important determinants of OS.
authors.affiliation: Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. tshenkier@bccancer.bc.ca
authors.forename: Tamara N
authors.initials: TN
authors.lastname: Shenkier
authors.forename: Nicholas
authors.initials: N
authors.lastname: Voss
authors.forename: Mukesh
authors.initials: M
authors.lastname: Chhanabhai
authors.forename: Randall
authors.initials: R
authors.lastname: Fairey
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: Paul
authors.initials: P
authors.lastname: Hoskins
authors.forename: Richard
authors.initials: R
authors.lastname: Klasa
authors.forename: James
authors.initials: J
authors.lastname: Morris
authors.forename: Susan E
authors.initials: SE
authors.lastname: O'Reilly
authors.forename: Tom
authors.initials: T
authors.lastname: Pickles
authors.forename: Laurie
authors.initials: L
authors.lastname: Sehn
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Connors
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000628:therapy*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003520:Cyclophosphamide / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use*
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate